複雑性尿路感染症治療の世界市場レポート 2025年

複雑性尿路感染症治療市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は6.4%で、121億3,000万米ドルに成長します。予測期間中の成長は、多剤耐性病原体の蔓延、精密医療への注目の高まり、ヘルスケア支出の増加、迅速診断検査の利用拡大、政府の取り組み、調査への資金提供などの要因によるものと考えられます。この時期の主な動向としては、診断技術の発展、新興国市場における医療アクセスの拡大、新規抗生物質の開発、診断ツールの技術革新、併用療法の採用などが挙げられます。

慢性腎臓病（CKD）の有病率の増加が複雑性尿路感染症治療市場の成長を牽引すると予想されます。CKDは、時間の経過とともに腎機能が徐々に低下する長期的な疾患です。CKD患者の増加は、糖尿病、高血圧、高齢化、肥満や喫煙などのライフスタイル要因の増加によるところが大きいです。複雑性尿路感染症の治療は、腎障害を悪化させ、腎機能を低下させ、CKDの進行を加速させる腎盂腎炎などの重症感染症を予防するのに役立つため、CKD患者にとって極めて重要です。この治療により、さらなる合併症や入院のリスクが軽減されます。例えば、2024年12月、オーストラリア保健福祉研究所は、2022年にオーストラリアで約2万1,800人がCKDが原因で死亡したと報告しました。さらに、2024年5月、Kidney Care UKは、英国では慢性腎臓病が毎年40,000～4万5,000人の早期死亡の原因となっていると述べています。このように、CKDの罹患率の上昇が複雑性尿路感染症治療市場の成長を促進しています。

複雑性尿路感染症治療市場の主な企業は、治療効果を向上させ、新興の多剤耐性病原体に対処するための新規抗生物質の開発を通じて、抗生物質耐性への対処に注力しています。複雑性尿路感染症に対する抗感染療法では、特に腎臓が侵された重症例では、標的抗生物質や抗菌剤を使用して感染を制御します。例えば、2024年2月、ドイツを拠点とするバイオ医薬品会社Allecra Therapeutics社は、米国食品医薬品局（FDA）が成人の複雑性尿路感染症の治療薬としてEXBLIFEP（セフェピム／エンメタゾバクタム）を承認したと発表しました。同社はまた、新規抗感染症治療薬の開発を奨励するGAIN法に基づき、5年間の独占販売権の延長も獲得しました。臨床試験では、セフェピム／エンメタゾバクタム投与群の79.1％が複合効果（臨床的治癒および微生物学的消失）を達成したのに対し、ピペラシリン／タゾバクタム投与群では58.9％でした。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界複雑性尿路感染症治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の複雑性尿路感染症治療市場：成長率分析
• 世界の複雑性尿路感染症治療市場の実績：規模と成長, 2019-2024
• 世界の複雑性尿路感染症治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界複雑性尿路感染症治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の複雑性尿路感染症治療市場：薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ペニシリンとその組み合わせ
• キノロン
• セファロスポリン
• アゾールとアムホテリシンB
• ニトロフラン
• 世界の複雑性尿路感染症治療市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 婦人科・泌尿器科クリニック
• ドラッグストア
• 小売薬局
• 世界の複雑性尿路感染症治療市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 尿道炎
• 膀胱炎
• 腎盂腎炎
• 世界の複雑性尿路感染症治療市場ペニシリンとその併用療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アミノペニシリン
• β-ラクタマーゼ阻害剤の併用
• 世界の複雑性尿路感染症治療市場キノロン類のサブセグメンテーション（種類別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• フルオロキノロン
• 非フルオロキノロン系
• 世界の複雑性尿路感染症治療市場セファロスポリンのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 第一世代セファロスポリン
• 第二世代セファロスポリン
• 第三世代セファロスポリン
• 第4世代セファロスポリン
• 第5世代セファロスポリン
• 世界の複雑性尿路感染症治療市場アゾール系薬剤とアムホテリシンBの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• トリアゾール
• イミダゾール
• ポリエン系抗真菌剤
• 世界の複雑性尿路感染症治療市場ニトロフランの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ニトロフラントイン
• フラゾリドン

第7章 地域別・国別分析

• 世界の複雑性尿路感染症治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の複雑性尿路感染症治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 複雑性尿路感染症治療市場：競合情勢
• 複雑性尿路感染症治療市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • Fresenius Kabi AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• GlaxoSmithKline plc
• bioMerieux SA
• Shionogi & Co. Ltd.
• Cipla Limited
• Santen Pharmaceutical Co. Ltd.
• Orchid Pharma Limited
• Melinta Therapeutics Inc.
• Spero Therapeutics Inc.
• Nabriva Therapeutics AG
• Venatorx Pharmaceuticals Inc.
• Recce Pharmaceuticals Ltd
• MerLion Pharmaceuticals Pte. Ltd.
• Entasis Therapeutics Holdings Inc.
• Allecra Therapeutics GmbH
• Allergan Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 複雑性尿路感染症治療市場2029：新たな機会を提供する国
• 複雑性尿路感染症治療市場2029：新たな機会を提供するセグメント
• 複雑性尿路感染症治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Complicated urinary tract infection (UTI) treatment refers to the management of urinary tract infections in individuals with underlying conditions that increase the risk of treatment failure. This treatment involves using targeted antibiotics and supportive therapies to address infections caused by resistant pathogens or other complications. It is particularly used for severe UTIs in patients with structural abnormalities, immunocompromised conditions, or catheter use, ensuring effective infection control and preventing further complications.

The main drug types for complicated urinary tract infection treatment include penicillin and combinations, quinolones, cephalosporins, azoles and amphotericin B, and nitrofurans. Penicillin and combinations consist of antibiotics derived from penicillin, often combined with beta-lactamase inhibitors to enhance their effectiveness against resistant bacteria. These treatments are distributed through various channels, such as hospital pharmacies, gynecology and urology clinics, and drug stores. They are used for a range of conditions, including urethritis, cystitis, and pyelonephritis.

The complicated urinary tract infection treatment market research report is one of a series of new reports from The Business Research Company that provides complicated urinary tract infection treatment market statistics, including the complicated urinary tract infection treatment industry global market size, regional shares, competitors with the complicated urinary tract infection treatment market share, detailed complicated urinary tract infection treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the complicated urinary tract infection treatment industry. This complicated urinary tract infection treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The complicated urinary tract infection treatment market size has grown strongly in recent years. It will grow from $8.87 billion in 2024 to $9.47 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth during the historical period can be attributed to factors such as the increasing prevalence of urinary tract infections, a rise in cases of antibiotic resistance, a growing geriatric population, higher hospitalization rates, and greater awareness about UTIs.

The complicated urinary tract infection treatment market size is expected to see strong growth in the next few years. It will grow to $12.13 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The growth during the forecast period can be attributed to factors such as the growing prevalence of multidrug-resistant pathogens, an increasing focus on precision medicine, rising healthcare expenditure, greater use of rapid diagnostic testing, government initiatives, and funding for research. Key trends during this period include advancements in diagnostic techniques, expanding healthcare access in emerging markets, the development of novel antibiotics, technological innovations in diagnostic tools, and the adoption of combination therapies.

The increasing prevalence of chronic kidney disease (CKD) is expected to drive growth in the complicated urinary tract infection treatment market. CKD is a long-term condition marked by the gradual decline in kidney function over time. The rise in CKD cases is largely due to the growing rates of diabetes, hypertension, aging populations, and lifestyle factors such as obesity and smoking. Treatment for complicated urinary tract infections is crucial for CKD patients as it helps prevent severe infections such as pyelonephritis, which can worsen kidney damage, impair renal function, and accelerate the progression of CKD. This treatment reduces the risk of further complications and hospitalizations. For example, in December 2024, the Australian Institute of Health and Welfare reported that CKD was responsible for approximately 21,800 deaths in Australia in 2022. Moreover, in May 2024, Kidney Care UK stated that chronic kidney disease causes 40,000 to 45,000 premature deaths each year in the UK. Thus, the rising incidence of CKD is driving the growth of the complicated urinary tract infection treatment market.

Key companies in the complicated urinary tract infection treatment market are focusing on addressing antibiotic resistance through the development of novel antibiotics to improve treatment effectiveness and tackle emerging multidrug-resistant pathogens. Anti-infective therapies for complicated urinary tract infections involve using targeted antibiotics or antimicrobial agents to control infections, particularly in severe cases where the kidneys are affected. For instance, in February 2024, Allecra Therapeutics, a Germany-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved EXBLIFEP (cefepime/enmetazobactam) for treating complicated urinary tract infections in adults. The company also secured a five-year marketing exclusivity extension under the GAIN Act, which encourages the development of new anti-infective therapies. Clinical studies showed that 79.1% of patients treated with cefepime/enmetazobactam achieved a composite response (clinical cure and microbiological eradication), compared to 58.9% in those treated with piperacillin/tazobactam.

In June 2024, Orchid Pharma Limited, an India-based pharmaceutical company, partnered with Cipla Limited to launch cefepime/enmetazobactam in India. This collaboration aims to leverage Cipla's distribution network to enhance the availability of cefepime/enmetazobactam, an antibiotic used to treat complicated urinary tract infections, including pyelonephritis. Cipla, a prominent India-based pharmaceutical company, focuses on providing advanced antibiotics and innovative healthcare solutions for treating complicated urinary tract infections.

Major players in the complicated urinary tract infection treatment market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., AstraZeneca PLC, Fresenius Kabi AG, GlaxoSmithKline plc, bioMerieux SA, Shionogi & Co. Ltd., Cipla Limited, Santen Pharmaceutical Co. Ltd., Orchid Pharma Limited, Melinta Therapeutics Inc., Spero Therapeutics Inc., Nabriva Therapeutics AG, Venatorx Pharmaceuticals Inc., Recce Pharmaceuticals Ltd, MerLion Pharmaceuticals Pte. Ltd., Entasis Therapeutics Holdings Inc., Allecra Therapeutics GmbH, Allergan Inc.

North America was the largest region in the complicated urinary tract infection treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in complicated urinary tract infection report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the complicated urinary tract infection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The complicated urinary tract infection treatment market consists of sales of antibiotics, antifungals, and combination therapy. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Complicated Urinary Tract Infection Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on complicated urinary tract infection treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for complicated urinary tract infection treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The complicated urinary tract infection treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Penicillin And combinations; Quinolones; Cephalosporin; Azoles And Amphotericin B; Nitro furans
• 2) By Distribution Channel: Hospital Pharmacies; Gynecology And Urology Clinics; Drug stores
• 3) By Application: Urethritis; Cystitis; Pyelonephritis
• Subsegments:
• 1) By Penicillin And Combinations: Aminopenicillins; Beta-Lactamase Inhibitor Combinations
• 2) By Quinolones: Fluoroquinolones; Non-Fluoroquinolones
• 3) By Cephalosporin: First-Generation Cephalosporins; Second-Generation Cephalosporins; Third-Generation Cephalosporins; Fourth-Generation Cephalosporins; Fifth-Generation Cephalosporins
• 4) By Azoles And Amphotericin B: Triazoles; Imidazoles; Polyene Antifungals
• 5) By Nitrofurans: Nitrofurantoin; Furazolidone
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; AbbVie Inc.; AstraZeneca PLC; Fresenius Kabi AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Complicated Urinary Tract Infection Treatment Market Characteristics

3. Complicated Urinary Tract Infection Treatment Market Trends And Strategies

4. Complicated Urinary Tract Infection Treatment Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Complicated Urinary Tract Infection Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Complicated Urinary Tract Infection Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Complicated Urinary Tract Infection Treatment Market Growth Rate Analysis
• 5.4. Global Complicated Urinary Tract Infection Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Complicated Urinary Tract Infection Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Complicated Urinary Tract Infection Treatment Total Addressable Market (TAM)

6. Complicated Urinary Tract Infection Treatment Market Segmentation

• 6.1. Global Complicated Urinary Tract Infection Treatment Market, Segmentation By Drug class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Penicillin And combinations
• Quinolones
• Cephalosporin
• Azoles And Amphotericin B
• Nitro furans
• 6.2. Global Complicated Urinary Tract Infection Treatment Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Gynecology and Urology Clinics
• Drug stores
• Retail Pharmacies
• 6.3. Global Complicated Urinary Tract Infection Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Urethritis
• Cystitis
• Pyelonephritis
• 6.4. Global Complicated Urinary Tract Infection Treatment Market, Sub-Segmentation Of Penicillin And Combinations, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Aminopenicillins
• Beta-Lactamase Inhibitor Combinations
• 6.5. Global Complicated Urinary Tract Infection Treatment Market, Sub-Segmentation Of Quinolones, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fluoroquinolones
• Non-Fluoroquinolones
• 6.6. Global Complicated Urinary Tract Infection Treatment Market, Sub-Segmentation Of Cephalosporin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• First-Generation Cephalosporins
• Second-Generation Cephalosporins
• Third-Generation Cephalosporins
• Fourth-Generation Cephalosporins
• Fifth-Generation Cephalosporins
• 6.7. Global Complicated Urinary Tract Infection Treatment Market, Sub-Segmentation Of Azoles And Amphotericin B, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Triazoles
• Imidazoles
• Polyene Antifungals
• 6.8. Global Complicated Urinary Tract Infection Treatment Market, Sub-Segmentation Of Nitrofurans, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nitrofurantoin
• Furazolidone

7. Complicated Urinary Tract Infection Treatment Market Regional And Country Analysis

• 7.1. Global Complicated Urinary Tract Infection Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Complicated Urinary Tract Infection Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Complicated Urinary Tract Infection Treatment Market

• 8.1. Asia-Pacific Complicated Urinary Tract Infection Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Complicated Urinary Tract Infection Treatment Market, Segmentation By Drug class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Complicated Urinary Tract Infection Treatment Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Complicated Urinary Tract Infection Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Complicated Urinary Tract Infection Treatment Market

• 9.1. China Complicated Urinary Tract Infection Treatment Market Overview
• 9.2. China Complicated Urinary Tract Infection Treatment Market, Segmentation By Drug class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Complicated Urinary Tract Infection Treatment Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Complicated Urinary Tract Infection Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Complicated Urinary Tract Infection Treatment Market

• 10.1. India Complicated Urinary Tract Infection Treatment Market, Segmentation By Drug class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Complicated Urinary Tract Infection Treatment Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Complicated Urinary Tract Infection Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Complicated Urinary Tract Infection Treatment Market

• 11.1. Japan Complicated Urinary Tract Infection Treatment Market Overview
• 11.2. Japan Complicated Urinary Tract Infection Treatment Market, Segmentation By Drug class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Complicated Urinary Tract Infection Treatment Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Complicated Urinary Tract Infection Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Complicated Urinary Tract Infection Treatment Market

• 12.1. Australia Complicated Urinary Tract Infection Treatment Market, Segmentation By Drug class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Complicated Urinary Tract Infection Treatment Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Complicated Urinary Tract Infection Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Complicated Urinary Tract Infection Treatment Market

• 13.1. Indonesia Complicated Urinary Tract Infection Treatment Market, Segmentation By Drug class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Complicated Urinary Tract Infection Treatment Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Complicated Urinary Tract Infection Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Complicated Urinary Tract Infection Treatment Market

• 14.1. South Korea Complicated Urinary Tract Infection Treatment Market Overview
• 14.2. South Korea Complicated Urinary Tract Infection Treatment Market, Segmentation By Drug class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Complicated Urinary Tract Infection Treatment Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Complicated Urinary Tract Infection Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Complicated Urinary Tract Infection Treatment Market

• 15.1. Western Europe Complicated Urinary Tract Infection Treatment Market Overview
• 15.2. Western Europe Complicated Urinary Tract Infection Treatment Market, Segmentation By Drug class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Complicated Urinary Tract Infection Treatment Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Complicated Urinary Tract Infection Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Complicated Urinary Tract Infection Treatment Market

• 16.1. UK Complicated Urinary Tract Infection Treatment Market, Segmentation By Drug class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Complicated Urinary Tract Infection Treatment Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Complicated Urinary Tract Infection Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Complicated Urinary Tract Infection Treatment Market

• 17.1. Germany Complicated Urinary Tract Infection Treatment Market, Segmentation By Drug class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Complicated Urinary Tract Infection Treatment Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Complicated Urinary Tract Infection Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Complicated Urinary Tract Infection Treatment Market

• 18.1. France Complicated Urinary Tract Infection Treatment Market, Segmentation By Drug class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Complicated Urinary Tract Infection Treatment Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Complicated Urinary Tract Infection Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Complicated Urinary Tract Infection Treatment Market

• 19.1. Italy Complicated Urinary Tract Infection Treatment Market, Segmentation By Drug class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Complicated Urinary Tract Infection Treatment Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Complicated Urinary Tract Infection Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Complicated Urinary Tract Infection Treatment Market

• 20.1. Spain Complicated Urinary Tract Infection Treatment Market, Segmentation By Drug class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Complicated Urinary Tract Infection Treatment Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Complicated Urinary Tract Infection Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Complicated Urinary Tract Infection Treatment Market

• 21.1. Eastern Europe Complicated Urinary Tract Infection Treatment Market Overview
• 21.2. Eastern Europe Complicated Urinary Tract Infection Treatment Market, Segmentation By Drug class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Complicated Urinary Tract Infection Treatment Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Complicated Urinary Tract Infection Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Complicated Urinary Tract Infection Treatment Market

• 22.1. Russia Complicated Urinary Tract Infection Treatment Market, Segmentation By Drug class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Complicated Urinary Tract Infection Treatment Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Complicated Urinary Tract Infection Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Complicated Urinary Tract Infection Treatment Market

• 23.1. North America Complicated Urinary Tract Infection Treatment Market Overview
• 23.2. North America Complicated Urinary Tract Infection Treatment Market, Segmentation By Drug class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Complicated Urinary Tract Infection Treatment Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Complicated Urinary Tract Infection Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Complicated Urinary Tract Infection Treatment Market

• 24.1. USA Complicated Urinary Tract Infection Treatment Market Overview
• 24.2. USA Complicated Urinary Tract Infection Treatment Market, Segmentation By Drug class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Complicated Urinary Tract Infection Treatment Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Complicated Urinary Tract Infection Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Complicated Urinary Tract Infection Treatment Market

• 25.1. Canada Complicated Urinary Tract Infection Treatment Market Overview
• 25.2. Canada Complicated Urinary Tract Infection Treatment Market, Segmentation By Drug class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Complicated Urinary Tract Infection Treatment Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Complicated Urinary Tract Infection Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Complicated Urinary Tract Infection Treatment Market

• 26.1. South America Complicated Urinary Tract Infection Treatment Market Overview
• 26.2. South America Complicated Urinary Tract Infection Treatment Market, Segmentation By Drug class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Complicated Urinary Tract Infection Treatment Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Complicated Urinary Tract Infection Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Complicated Urinary Tract Infection Treatment Market

• 27.1. Brazil Complicated Urinary Tract Infection Treatment Market, Segmentation By Drug class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Complicated Urinary Tract Infection Treatment Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Complicated Urinary Tract Infection Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Complicated Urinary Tract Infection Treatment Market

• 28.1. Middle East Complicated Urinary Tract Infection Treatment Market Overview
• 28.2. Middle East Complicated Urinary Tract Infection Treatment Market, Segmentation By Drug class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Complicated Urinary Tract Infection Treatment Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Complicated Urinary Tract Infection Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Complicated Urinary Tract Infection Treatment Market

• 29.1. Africa Complicated Urinary Tract Infection Treatment Market Overview
• 29.2. Africa Complicated Urinary Tract Infection Treatment Market, Segmentation By Drug class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Complicated Urinary Tract Infection Treatment Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Complicated Urinary Tract Infection Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Complicated Urinary Tract Infection Treatment Market Competitive Landscape And Company Profiles

• 30.1. Complicated Urinary Tract Infection Treatment Market Competitive Landscape
• 30.2. Complicated Urinary Tract Infection Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Fresenius Kabi AG Overview, Products and Services, Strategy and Financial Analysis

31. Complicated Urinary Tract Infection Treatment Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline plc
• 31.2. bioMerieux SA
• 31.3. Shionogi & Co. Ltd.
• 31.4. Cipla Limited
• 31.5. Santen Pharmaceutical Co. Ltd.
• 31.6. Orchid Pharma Limited
• 31.7. Melinta Therapeutics Inc.
• 31.8. Spero Therapeutics Inc.
• 31.9. Nabriva Therapeutics AG
• 31.10. Venatorx Pharmaceuticals Inc.
• 31.11. Recce Pharmaceuticals Ltd
• 31.12. MerLion Pharmaceuticals Pte. Ltd.
• 31.13. Entasis Therapeutics Holdings Inc.
• 31.14. Allecra Therapeutics GmbH
• 31.15. Allergan Inc.

32. Global Complicated Urinary Tract Infection Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Complicated Urinary Tract Infection Treatment Market

34. Recent Developments In The Complicated Urinary Tract Infection Treatment Market

35. Complicated Urinary Tract Infection Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Complicated Urinary Tract Infection Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Complicated Urinary Tract Infection Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Complicated Urinary Tract Infection Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer